886501-77-5 Usage
Uses
Used in Pharmaceutical Industry:
2,3-Difluoro-6-methoxybenzylamine is utilized as a building block for the preparation of various pharmaceuticals. Its incorporation into the molecular structures of drugs allows for the enhancement of their therapeutic properties, such as potency, selectivity, and bioavailability.
Used in Agrochemical Industry:
In the agrochemical sector, 2,3-difluoro-6-methoxybenzylamine serves as a key component in the synthesis of compounds with pesticidal or herbicidal activities. Its unique fluorinated and methoxylated structure contributes to the development of more effective and environmentally friendly agrochemicals.
Used in Research and Development:
2,3-Difluoro-6-methoxybenzylamine is employed as a precursor in the research and development of new drugs. Its unique reactivity and structural features make it a valuable tool for exploring novel chemical spaces and discovering potential therapeutic agents.
Used in Organic Synthesis:
As a versatile intermediate in organic synthesis, 2,3-difluoro-6-methoxybenzylamine is used to synthesize a wide range of bioactive molecules. Its fluorinated and methoxylated benzene ring can be further modified or functionalized to access diverse chemical entities with potential applications in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 886501-77-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,5,0 and 1 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 886501-77:
(8*8)+(7*8)+(6*6)+(5*5)+(4*0)+(3*1)+(2*7)+(1*7)=205
205 % 10 = 5
So 886501-77-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H9F2NO/c1-12-7-3-2-6(9)8(10)5(7)4-11/h2-3H,4,11H2,1H3
886501-77-5Relevant articles and documents
TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
-
, (2018/04/11)
A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.
